DXCM logo DexCom +
DexCom
+

DexCom (DXCM) Business News

Track DexCom in real time with a live news feed covering DexCom stock news, official press releases, company announcements, and an archive of historical DexCom news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Why DexCom (DXCM) is a Top Growth Stock for the Long-Term

Zacks Investment Research

10:47 AM | Wednesday | May 27, 2026

news photo
Loading...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read full article redirect
10:47 AM | Wednesday | May 27, 2026

Why DexCom (DXCM) is a Top Growth Stock for the Long-Term

Zacks Investment Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read full article arrow
News Thumbnail
9:07 AM | Wednesday | May 27, 2026

Signos grows foothold in weight-loss wave fueled by GLP-1s with its AI health data tracking

CNBC

Health tech startup Signos announced a $20 million funding round and expanded its partnership with medical device giant Dexcom. Signos makes an AI-powered glucose monitoring system designed to help with healthy weight loss, the first of its kind to be cleared by the FDA in 2025.

Read full article arrow
News Thumbnail
10:47 AM | Wednesday | May 27, 2026

Why DexCom (DXCM) is a Top Growth Stock for the Long-Term

Zacks Investment Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read full article arrow
News Thumbnail
9:07 AM | Wednesday | May 27, 2026

Signos grows foothold in weight-loss wave fueled by GLP-1s with its AI health data tracking

CNBC

Health tech startup Signos announced a $20 million funding round and expanded its partnership with medical device giant Dexcom. Signos makes an AI-powered glucose monitoring system designed to help with healthy weight loss, the first of its kind to be cleared by the FDA in 2025.

Read full article arrow
News Thumbnail
10:47 AM | Tuesday | May 26, 2026

Dexcom warns patients as stolen glucose sensors hit the market

Reuters

Medical device maker Dexcom said on Tuesday some of its glucose sensors ​slated for destruction were instead stolen and ‌sold, prompting the company to warn users not to use products from two affected lots.

Read full article arrow
News Thumbnail
9:30 AM | Tuesday | May 26, 2026

Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users

Business Wire

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties. Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine part of the company's quality control process. Sensors identified.

Read full article arrow
News Thumbnail
5:40 PM | Friday | May 22, 2026

Dexcom: A Medical Platform Play Gaining From AI, Not Disrupted By It

Seeking Alpha

Dexcom (DXCM) is leveraging AI to drive operational efficiency and product innovation, positioning itself as a platform medical provider in CGM. DXCM achieved 300 basis points in operating margin improvement, with sustained cost savings and strong FCF margin outpacing healthcare equipment peers. Stelo CGM, built with Google AI, targets the large prediabetic market, offering significant customer base expansion potential without requiring a prescription.

Read full article arrow
News Thumbnail
9:57 PM | Thursday | May 21, 2026

DexCom Might Finally Be Cheap Enough

Seeking Alpha

DexCom is now rated a 'Buy' as improved fundamentals and a 15% lower stock price present a more attractive entry. Q1/26 results showed 15% revenue growth, and 90.9% operating income growth and raised 2026 guidance for both revenue and margins. Key growth drivers include international expansion, increased U.S.
coverage for type 2 diabetics, and a $1B share buyback in 2026.

Read full article arrow
News Thumbnail
10:50 AM | Wednesday | May 20, 2026

Here's Why DexCom (DXCM) is a Strong Momentum Stock

Zacks Investment Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read full article arrow
News Thumbnail
11:58 AM | Tuesday | May 19, 2026

DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany

Zacks Investment Research

DexCom gains 5.6% after announcing plans to launch Dexcom Flex in Germany, expanding CGM access for Type 2 diabetes patients using basal insulin or oral meds.

Read full article arrow
News Thumbnail
8:00 AM | Monday | May 18, 2026

Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany

GuruFocus

DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for adults w

Read full article arrow
News Thumbnail
7:31 AM | Monday | May 18, 2026

Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany

Business Wire

SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available in Germany soon. Dexcom Flex is made for people using basal insulin, oral medications or GLP-1 receptor agonists, expanding access to CGM technology for a broader Type 2 diabetes population. D.

Read full article arrow
News Thumbnail